Option chain shows key data for Opus Genetics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Opus Genetics.

Opus Genetics (NASDAQ:IRD) Stock, Option Chain

Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Inc

Iren SpA

Iridium Communications Inc - Common Stock

Iridium Communications Inc

"Overall, based on factors within Orion's control and despite the strengthening FX headwind, we continue to expect modest growth in 2025, building upon the structurally improved returns our company has generated over the past several years," the company said.

News

Orion Says Commenced An Initiative In Q4 To Reduce Its Non-plant Workforce By ~6% And Expects To Realize $6M In Annualized Cost Savings In 2025

Weaker than anticipated Rubber segment volumes late in the fourth quarter and slightly less favorable Specialty segment mix were also factors and would have positioned the company at the lower end of guidance, excluding the items.

Guidance

Orion Now Expects 2024 Adjusted EBITDA To Be Nominally Below Guidance Range Of $305M - $315M, Due Primarily To Foreign Exchange Translation Impacts

SPX Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) has outperformed the market over the past 10 years by 10.51% on an annualized basis producing an average annual return of 21.88%. Currently, SPX Techs has a market capitalization of $6.87 billion. 
Buying $1000 In SPXC: If an investor had bought $1000 of SPXC stock 10 years ago, it would be worth $7,231.81 today based on a price of $148.29 for SPXC at the time of writing.
<h3>SPX Techs's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736977507_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SPXC

Here's How Much $1000 Invested In SPX Techs 10 Years Ago Would Be Worth Today

The approximately 260-mile transmission project will support current and growing energy needs of the company's Wyoming customers, including data centers, while reducing dependence on third-party transmission systems.&nbsp;

Black Hills Says Wyoming Electric Utility Has Successfully Placed In Service The Initial 12-mile Segment

WIIM

SNAP

Snap and Meta shares are trading lower following a report suggesting Trump is considering an executive order hoping to save TikTok from a US ban.

<a href="https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/" title="https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/">https://www.washingtonpost.com/technology/2025/01/15/trump-tiktok-ban-executive-order/</a>

Social Media

General

Washington Post: 'Trump considers executive order hoping to 'save TikTok' from ban in U.S. law'

McKenna most recently served as President and Chief Executive Officer of Walmart International until her retirement in January 2024, where she was responsible for all aspects of Walmart's business outside the United States.

Management

Delta Air Lines Board Adds Judith Mckenna As Its Newest Member, Effective February 7, 2025

Flowco Holdings Inc. ("Flowco"), a provider of production optimization, artificial lift and methane abatement solutions for the oil and natural gas industry, today announced the pricing of its initial public offering of 17,800,000 shares of its Class A common stock at a public offering price of $24.00 per share. In addition, the underwriters will have a 30-day option to purchase up to an additional 2,670,000 shares of Class A common stock from Flowco at the initial public offering price, less underwriting discounts and commissions. Flowco's Class A common stock is expected to begin trading on the New York Stock Exchange on January 16, 2025 under the ticker symbol "FLOC." The offering is expected to close on January 17, 2025, subject to the satisfaction of customary closing conditions.
Flowco intends to use the net proceeds that it receives from the proposed offering to redeem certain equity interests from certain non-affiliate holders, and with respect to the remainder, repay indebtedness under its existing credit agreement.

IPOs

FLOC

Flowco Announces The Pricing Of Its Initial Public Offering Of 17.8M Shares Of Its Class A Common Stock At A Public Offering Price Of $24.00 Per Share; Expected To Begin Trading On The New York Stock Exchange On January 16, 2025

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) released its Q4 earnings on Wednesday, January 15, 2025 at 04:20 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Home BancShares missed estimated earnings by -4.0%, reporting an EPS of $0.5 versus an estimate of $0.52.
Revenue was up $12.75 million from the same period last year.
<h3>Earnings History Overview</h3>
The company missed on EPS by $0.03 in the previous quarter, leading to a 2.0% drop share price change the next day.
Here's a look at Home BancShares's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.49</td>
<td>0.46</td>
<td>0.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.52</td>
<td>0.49</td>
<td>0.51</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>258.90M</td>
<td>247.21M</td>
<td>240.46M</td>
<td>243.07M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>258.00M</td>
<td>254.60M</td>
<td>246.39M</td>
<td>245.62M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Home BancShares <a href="https://www.benzinga.com/quote/HOMB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

HOMB

Recap: Home BancShares Q4 Earnings

Rio Tinto Says Pilbara Iron Ore Operations Produced 328.0 Million Tonnes In 2024, With Shipments Of 328.6 Million Tonnes, Each 1% Lower Than 2023

<ul>
<li>Accelerates the tax-free spin-off of its Electronics business, now targeting November 1, 2025</li>
<li>DuPont to retain the Water business within its portfolio</li>
<li>Reaffirms fourth quarter and full year 2024 net sales, operating EBITDA and adjusted EPS financial guidance ahead of its February 11th earnings call</li>
</ul>
WILMINGTON,&nbsp;Del., Jan. 15, 2025 /PRNewswire/ -- DuPont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) today announced the acceleration of the separation of its Electronics business and is now targeting November 1, 2025 to complete the transaction. This decision recognizes the size and importance of Electronics to the overall shareholder value creation opportunity and DuPont's desire to complete the separation as quickly as possible.
Additionally, DuPont no longer intends to separate its Water business. The company evaluated all strategic alternatives and concluded the best path to generate value is for the Water business to remain in the DuPont portfolio. This also enhances DuPont's ability to continue optimizing its portfolio following the Electronics separation.
"We remain confident in the opportunity to create significant shareholder value through the separation of the Electronics business," said Ed Breen, DuPont Executive Chairman. "Achieving an independent Electronics company as soon as possible is the right decision for our shareholders."
"We remain excited about the value creation opportunity for DuPont following the Electronics separation," added Lori Koch, DuPont Chief Executive Officer. "The decision for Water to remain with DuPont provides the new organization with greater strategic flexibility over time and another high growth business alongside Healthcare. We continue to have conviction in the attractive outlook for Water and expect 2025 to be a strong year for the business."&nbsp;
Reaffirms Fourth Quarter and Full Year 2024 Financial Outlook
DuPont reaffirms its fourth quarter and full year 2024 financial guidance for net sales, operating EBITDA and adjusted EPS as provided on November 5, 2024 as part of its third quarter earnings release, including the expected continued improved performance in Water.
 &nbsp;

Dividends

DuPont Accelerates The Tax-Free Spin-Off Of Its Electronics Business, Now Targeting November 1, 2025; To Retain The Water Business Within Its Portfolio; Reaffirms Q4 And FY24 Financial Outlook

<a href="https://hindenburgresearch.com/gratitude/" title="https://hindenburgresearch.com/gratitude/">https://hindenburgresearch.com/gratitude/</a>

Short Sellers

CVNA

RBLX

SMCI

Hindenburg Research Founder Nate Anderson Said He Has Made The Decision To Disband The Firm

As a result, the Company has decided to voluntarily revise its historical adjusted operating income for the relevant periods, resulting in a decrease in after-tax adjusted operating income of $115 million or $0.31 per Common share for the nine months ended September 30, 2024, and $24 million or $0.07 per Common share for the nine months ended September 30, 2023, compared to previously reported amounts(1).&nbsp;
These revisions had no impact to GAAP net income, book value, statutory results, or the historical or expected future cash flows of these products.

Prudential Financial Says Identified An Immaterial Error During Q4 In Application Of Adjusted Operating Income - Filing

Amphenol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) has outperformed the market over the past 15 years by 7.09% on an annualized basis producing an average annual return of 18.86%. Currently, Amphenol has a market capitalization of $85.54 billion. 
Buying $1000 In APH: If an investor had bought $1000 of APH stock 15 years ago, it would be worth $12,870.75 today based on a price of $70.95 for APH at the time of writing.
<h3>Amphenol's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736976607_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

NEXA

Nexa Resources Adopts New Dividend Policy; Targets Annual Dividend Of Up To 20% Of Free Cash Flow Pre-events, With Minimum Payment Of $0.08 Per Share

"Exceptional holiday demand and the effective execution of our strategic initiatives fueled our fourth-quarter outperformance, and gives us confidence that we will exceed our prior 2024 guidance,"&nbsp;stated Charlie Youakim, Sezzle Chairman and CEO.

SEZL

Sezzle Expects Exceeding 2024 Revenue And Income Guidance Provided In Conjunction With Its Q3 Earnings Release.

MetLife Responds To Report On Cyberattack, Says "We are aware of a cyberattack impacting Ecuador-based Fondo Genesis. As Fondo Genesis operates separately from MetLife's enterprise systems, this incident has not impacted any other parts of the MetLife business. Fondo Genesis is a financial services company operating only in Ecuador that is owned by Chilean pension manager ProVida, a subsidiary of MetLife."

Mandy Long will step down as Chief Executive Officer and from the Board of Directors, transitioning to serve as a Company advisor.
McAleenan currently serves as BigBear.ai's President.

BBAI

BigBear.ai Appoints Kevin McAleenan As CEO And Member Of  Board, Effective January 15, 2025, Succeeding Mandy Long

Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.52 by 3.85 percent. The company reported quarterly sales of $258.36 million which beat the analyst consensus estimate of $256.70 million by 0.65 percent. This is a 5.19 percent increase over sales of $245.62 million the same period last year.

Earnings Beats

Earnings Misses

Home BancShares Q4 2024 Adj EPS $0.50 Misses $0.52 Estimate, Sales $258.36M Beat $256.70M Estimate

Compass Diversified Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CODI#NYSE">CODI</a>), an owner of leading middle market businesses (the "Company" or "CODI"), announced today that on January 15, 2025, it entered into a Seventh Amended and Restated Management Services Agreement with Compass Group Management LLC, the Company's Manager (the "Amendment"). The Amendment, commencing in the first quarter beginning on January 1, 2025, restructures the management fee under the existing Management Services Agreement to consist of a base management fee and an incentive management fee. Pursuant to the Amendment, the base management fee will be (i) 2.0% of the Company's adjusted net assets when the adjusted net assets are less than or equal to $3.5 billion (the "Initial Threshold Fee"), (ii) the Initial Threshold Fee, plus 1.25% of the amount of adjusted net assets exceeding $3.5 billion when the adjusted net assets are more than $3.5 billion but less than $10 billion, or (iii) 1.5% of the Company's adjusted net assets when the adjusted net assets are $10 billion or more.
The incentive management fee will be 0.25% of the amount of adjusted net assets exceeding $3.5 billion, when the adjusted net assets are more than $3.5 billion but less than $10 billion. The incentive management fee is only earned if the Company's annualized internal rate of return on equity for the trailing three years exceeds 12%. Such incentive management fee is also subject to approval by the Compensation Committee of the Company's Board of Directors.

CODI

Compass Diversified Enters Seventh Amended Management Services Agreement, Restructures Fees Effective Q1 2025; Base Fee 2% Up To $3.5B, 1.25% Over $3.5B to $10B, 1.5% Over $10B; Incentive Fee 0.25% Over $3.5B To $10B Subject To 12% Return Approval

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)

Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.05, revenue of $3.87M beats by $1.57M

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited retinal disease develo...

Opus Genetics reinstated with a Buy at H.C. Wainwright

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Elevation Onc...

Analysts' Top Healthcare Picks: Opus Genetics (IRD), Elevation Oncology (ELEV)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and Brainstorm...

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)

Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on Opus Genetics (IRD – Research Report) and keeping the price target at $9....

Buy Rating Affirmed for Opus Genetics Amid Promising OPGx-LCA5 Treatment Results and Regulatory Progress

Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, SPA,...

Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330

Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Opus Genetics (IRD – Research Report). The associated price target...

Comments

Opus Genetics

Opus Genetics (IRD) Options

Opus Genetics (NASDAQ:IRD) Stock, Option Chain

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga